Inherited antithrombin deficiency and end stage renal disease

Medical Science Monitor

Volumn 11, Issue 11, 2005, Pages

  Hara, Tomohiko ^a   Naito, Katsusuke ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antithrombin deficiency; Deep vein thrombus; End stage renal disease; Renal failure; Renal vein thrombus; Thrombophilic disorder

Indexed keywords

ANDROGEN; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; HEPARIN; NAFAMSTAT MESILATE; WARFARIN;

ANGIOGRAPHY; ANTICOAGULANT THERAPY; ANTITHROMBIN DEFICIENCY; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; KIDNEY VEIN THROMBOSIS; LABORATORY TEST; LUNG EMBOLISM; PERITONEAL DISEASE; PHLEBOGRAPHY; PREVALENCE; REVIEW; RISK FACTOR; TREATMENT INDICATION;

ANIMALS; ANTITHROMBIN III DEFICIENCY; ANTITHROMBINS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MICE; RENAL DIALYSIS; VENOUS THROMBOSIS;

EID: 28144443618     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Egeberg O: Inherited Antithrombin Deficiency Causing Thrombophilia. Thromb Diath Haemorrh, 1965; 13: 516-30
2. Beresford CH: Antithrombin III deficiency. Blood Rev, 1988; 2(4): 239-50
3. Susan C Bock: Antithrombin III and heparin cofactor II. In: Col man RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, PA, LippincottWilliams & Wilkins, 2001; 321-33
4. Fell C, Ivanovic N, Johnson SA, Seegers WH: Differentiation of plasma antithrombin activities. Proc Soc Exp Biol Med, 1954; 85(2): 199-202
5. Mammen EF: Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost, 1998; 24(1): 19-25
6. Sakuragawa N: Regulation of thrombosis and hemostasis by antithrombin. Semin Thromb Hemost, 1997; 23(6): 557-62
7. Yanada M, Kojima T, Ishiguro K et al: Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombin-deficient mice. Blood, 2002; 99(7): 2455-58
8. Bauer KA, Rosenberg RD: Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol, 1991; 28(1): 10-18
9. Blajchman MA, Austin RC, Fernandez-Rachubinski F, Sheffield WP: Molecular basis of inherited human antithrombin deficiency. Blood, 1992; 80(9): 2159-71
10. van Boven HH, Lane DA: Antithrombin and its inherited deficiency states. Semin Hematol, 1997; 34(3): 188-204
11. Pratt CW, Church FC: Antithrombin: structure and function. Semin Hematol, 1991; 28(1): 3-9
12. Tollefsen DM: Antithrombin Deficiency. In: Scriver CR, Beaudet AL, Valle D, Sly WS, Childs B, Kinder KW et al editors. The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 2000; 4455-71
13. Perry DJ, Carrell RW: Molecular genetics of human antithrombin deficiency. Hum Mutat, 1996; 7(1): 7-22
14. David D, Ribeiro S, Ferrao L et al: Molecular basis of inherited antithrombin deficiency in Portuguese families: identification of genetic alterations and screening for additional thrombotic risk factors. Am J Hematol, 2004; 76(2): 163-71
15. nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost, 1997; 77(1): 197-211
16. Ishiguro K, Kojima T, Kadomatsu K et al: Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest, 2000; 106(7): 873-78
17. Tait RC, Walker ID, Perry DJ et al: Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thromb Haemost, 1991; 65: 839
18. Odegard OR, Abildgaard U: Antithrombin III: critical review of assay methods. Significance of variations in health and disease. Haemostasis, 1978; 7(2-3): 127-34
19. Rosenberg RD: Actions and interactions of antithrombin and heparin. N Engl J Med, 1975; 292(3): 146-51
20. Chowdhury V, Lane DA, Mille B et al: Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost, 1994; 72(2): 198-202
21. Hirsh J, Piovella F, Pini M: Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med, 1989; 87(3B): 34S-38S
22. Mateo J, Oliver A, Borrell M et al: Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism - results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost, 1997; 77(3): 444-51
23. Vikydal R, Korninger C, Kyrle PA et al: The prevalence of hereditary antithrombin-III deficiency in patients with a history of venous thromboembolism. Thromb Haemost, 1985; 54(4): 744-45
24. Demers C, Ginsberg JS, Hirsh J et al: Thrombosis in antithrombin-III- deficient persons. Report of a large kindred and literature review. Ann Intern Med, 1992; 116(9): 754-61
25. Simioni P, Sanson BJ, Prandoni P et al: Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost, 1999; 81(2): 198-202
26. Rosendaal FR, Heijboer H, Briet E et al: Mortality in hereditary antithrombin-III deficiency - 1830 to 1989. Lancet, 1991; 337(8736): 260-62
27. van Boven HH, Vandenbroucke JP, Westendorp RG, Rosendaal FR Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost, 1997; 77(3): 452-55
28. Conard J, Brosstad F, Lie Larsen M et al: Molar antithrombin concentration in normal human plasma. Haemostasis, 1983; 13(6): 363-68
29. Tait RC, Walker ID, Islam SI et al: Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol, 1993; 84(3): 476-80
30. Conlan MG, Folsom AR, Finch A et al: Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Thromb Haemost, 1994; 72(4): 551-56
31. Andrew M, Paes B, Milner R et al: Development of the human coagulation system in the full-term infant. Blood, 1987; 70(1): 165-72
32. Tran TH, Duckert F: Influence of heparin cofactor II (HCII) on the determination of antithrombin III (AT). Thromb Res, 1985; 40(4): 571-76
33. Conard J, Bara L, Horellou MH, Samama MM: Bovine or human thrombin in amidolytic at III assays. Influence of heparin cofactor II. Thromb Res, 1986; 41(6): 873-78
34. Andersson N-E, Menschik M, van Voorthuizen H: New chromogenic ATIII activity kit which is insensitive to heparin cofactor II and designed for use on automated instruments. Thromb Haemost, 1991; 65: 912
35. Downing MR, Bloom JW, Mann KG: Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry, 1978; 17(13): 2649-53
36. Kyrle PA, Eichinger S: Deep vein thrombosis. Lancet, 2005; 365(9465): 1163-74
37. Mitchell L, Piovella F, Ofosu F, Andrew M: Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood, 1991; 78(9): 2299-304
38. Heijboer H, Brandjes DP, Buller HR et al: Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med, 1990; 323(22): 1512-16
39. Kottke-Marchant K, Duncan A: Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med, 2002; 126(11): 1326-36
40. Ginsberg JS: Management of venous thromboembolism. N Engl J Med, 1996; 335(24): 1816-28
41. Leclerc JR, Geerts W, Panju A et al: Management of anti-thrombin III deficiency during pregnancy without administration of anti-thrombin III. Thromb Res, 1986; 41(4): 567-73
42. Nielsen LE, Bell WR, Borkon AM, Neill CA: Extensive thrombus formation with heparin resistance during extracorporeal circulation. A new presentation of familial antithrombin III deficiency. Arch Intern Med, 1987; 147(1): 149-52
43. Mannucci PM, Tripodi A, Mari D: Congenital deficiencies of anticoagulant proteins (antithrombin III and protein C). Haematologica, 1984; 69(6): 730-46
44. Menache D, O'Malley JP, Schorr JB et al: Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood, 1990; 75(1): 33-39
45. Menache D: Replacement therapy in patients with hereditary antithrombin III deficiency. Semin Hematol, 1991; 28(1): 31-38
46. Eyster ME, Parker ME: Treatment of familial antithrombin-III deficiency with danazol. Haemostasis, 1985; 15(2): 119-25
47. Tengborn L, Bergqvist D: Surgery in patients with congenital antithrombin III deficiency. Acta Chir Scand, 1988; 154(3): 179-83
48. Hara T, Jojima K, Takeuchi K et al: Intraoperative management of a congenital antithrombin deficient patient on chronic hemodialysis. Thromb Haemost, 2004; 92(1): 208-10
49. Ambruso DR, Leonard BD, Bies RD et al: Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood, 1982; 60(1): 78-83
50. Knot EA, de Jong E, ten Cate JW et al: Purified radiolabeled antithrombin III metabolism in three families with hereditary AT III deficiency: application of a three-compartment model. Blood, 1986; 67(1): 93-98
51. Prandoni P, Lensing AW, Cogo A et al: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med, 1996; 125(1): 1-7
52. Schulman S, Granqvist S, Holmstrom M et al: The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med, 1997; 336(6): 393-98
53. Petitti DB, Strom BL, Melmon KL: Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med, 1986; 81(2): 255-59
54. Keusch G: [Thrombotic complications in the nephrotic syndrome]. Schweiz Med Wochenschr, 1989; 119(31-32): 1080-85
55. Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA: Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med, 1978; 65(4): 607-13
56. O'Shea SI, Ortel TL, Kovalik EC: Alternative methods of anucoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial, 2003; 16(1): 61-67
57. Knoll GA, Wells PS, Young D et al: Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol, 2005; 16(4): 1108-14
58. Heidenreich S, Dercken C, August C et al: High rate of acute rejections in renal allograft recipients with thrombophUic risk factors. J Am Soc Nephrol, 1998; 9(7): 1309-13
59. Toulon P, Moulonguet-Doleris L, Costa JM, Aiach M: Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis. Thromb Haemost, 1991; 65(1): 20-24
60. Bajo MA, del Peso G, Jimenez V et al: Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders. Adv Perit Dial, 2000; 16: 170-73
61. Yoshida K, Saka M, Kaneko Y et al: Study of serum level of antithrombin-III antigen, antithrombin activity, and its ratio of AT-III-heparin complex formation in maintenance hemodialysis patients. Nippon Jinzo Gakkai Shi, 1989; 31(11): 1171-77
62. Ota K, Akizawa T, Hirasawa Y et al: Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant, 2003; 18(8): 1623-30
63. Matsuo T, Koide M, Kario K: Development of argatroban, a direct thrombin inhibitor, and its clinical application. Semin Thromb Hemost, 1997; 23(6): 517-22
64. Bhattacharyya M, Makharia G, Karman M et al: Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol, 2004; 121(6): 844-47
65. Fujii S, Hitomi Y: New synthetic inhibitors of Clr, Cl esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta, 1981; 661(2): 342-45
66. Hitomi Y, Ikari N, Fujii S: Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis, 1985; 15(3): 164-68
67. Akizawa T, Kitaoka T, Sato M et al: Comparative clinical trial of regional anticoagulation for hemodialysis. ASAIO Trans, 1988; 34(3): 176-78
68. Hu ZJ, Iwama H, Suzuki R et al: Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate. Intensive Care Med, 1999; 25(5): 524-27
69. Matsuo T, Kario K, Nakao K et al: Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis, 1993; 23(3): 135-41
70. Kujovich JL: Thrombophilia and thrombotic problems in renal transplant patients. Transplantation, 2004; 77(7): 959-64
71. Humar A, Johnson EM, Gillingham KJ et al: Venous thromboembolic complications after kidney and kidney-pancreas transplantation: A multivariate analysis. Transplantation, 1998; 65(2): 229
72. van Roye SF, van der Vliet JA, Hoitsma AJ et al: Causes of early vascular complications in renal transplantation. Transplant Proc, 1993; 25(4): 2609
73. Bakir N, Sluiter WJ, Ploeg RJ et al: Primary renal graft thrombosis. Nephrol Dial Transplant, 1996; 11(1): 140-47
74. Ojo AO, Hanson JA, Wolfe RA et al: Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. Kidney Int, 1999; 55(5): 1952-60
75. Ramirez PJ, Gohh RY, Kestin A et al: Renal allograft loss due to proximal extension of ileofemoral deep venous thrombosis. Clin Transplant, 2002; 16(4): 310-13
76. Deira J, Alberca I, Lerma JL et al: Changes in coagulation and fibrinolysis in the postoperative period immediately after kidney transplantation in patients receiving OKT3 or cyclosporine A as induction therapy. Am J Kidney Dis, 1998; 32(4): 575-81
77. Torry RJ, Labarrere CA, Gargiulo P, Faulk WP: Natural anticoagulant and fibrinolytic pathways in renal allograft failure. Transplantation, 1994; 58(8): 926-31
78. Kasiske BL, Cangro CB, Hariharan S et al: The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant, 2001; 1 (Suppl.2): 3-95
79. Friedman GS, Meier-Kriesche HU, Kaplan B et al: Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation, 2001; 72(6): 1073-78
80. Morrissey PE, Ramirez PJ, Gohh RY et al: Management of thrombophilia in renal transplant patients. Am J Transplant, 2002; 2(9): 872-76
81. Alwakeel J, Gader AM, Hurieb S et al: Coagulation inhibitors and fibrinolytic parameters in patients on peritoneal dialysis and haemodialysis. Int Urol Nephrol, 1996; 28(2): 255-61
82. Lai KN, Yin JA, Yuen PM, Li PK: Protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis and hemodialysis. Nephron, 1990; 56(3): 271-76